Quince Therapeutics, Inc.: current liabilities
Current liabilities for Quince Therapeutics, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Quince Therapeutics, Inc. financial histories
What this measure means
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
Exact concept: us-gaap:LiabilitiesCurrent. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2018-12-31 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 43,226,000 | USD | 2026-04-10 | 10-K · 0001193125-26-151364 |
| At date | 2024-12-31 | 7,278,000 | USD | 2026-04-10 | 10-K · 0001193125-26-151364 |
| At date | 2023-12-31 | 9,572,000 | USD | 2025-03-24 | 10-K · 0001662774-25-000012 |
| At date | 2022-12-31 | 3,069,000 | USD | 2024-04-01 | 10-K · 0000950170-24-039440 |
| At date | 2021-12-31 | 14,222,000 | USD | 2023-03-15 | 10-K · 0000950170-23-008148 |
| At date | 2020-12-31 | 16,996,000 | USD | 2022-03-01 | 10-K · 0000950170-22-002571 |
| At date | 2019-12-31 | 8,892,000 | USD | 2021-03-01 | 10-K · 0001564590-21-009867 |
| At date | 2018-12-31 | 1,457,000 | USD | 2020-03-16 | 10-K · 0001564590-20-011165 |
Related financial histories
- Quince Therapeutics, Inc.: total assets
- Quince Therapeutics, Inc.: total liabilities
- Quince Therapeutics, Inc.: stockholders equity
- Quince Therapeutics, Inc.: cash and cash equivalents
- Quince Therapeutics, Inc.: net income or loss
- Quince Therapeutics, Inc.: operating cash flow
- Quince Therapeutics, Inc.: capital expenditure payments
- Quince Therapeutics, Inc.: financing cash flow
- Quince Therapeutics, Inc.: investing cash flow
- Quince Therapeutics, Inc.: retained earnings or deficit
- Quince Therapeutics, Inc.: basic weighted-average shares
- Quince Therapeutics, Inc.: diluted weighted-average shares
- Quince Therapeutics, Inc.: basic earnings per share
- Quince Therapeutics, Inc.: diluted earnings per share
- Quince Therapeutics, Inc.: income tax expense or benefit
- Quince Therapeutics, Inc.: net property, plant and equipment
- Quince Therapeutics, Inc.: share-based compensation expense
- Quince Therapeutics, Inc.: operating income or loss
- Quince Therapeutics, Inc.: current assets
- Quince Therapeutics, Inc.: current accounts payable
- Quince Therapeutics, Inc.: goodwill carrying amount
- Quince Therapeutics, Inc.: net finite-lived intangible assets
- Quince Therapeutics, Inc.: operating expenses
- Quince Therapeutics, Inc.: research and development expense
Inspect the source
- Entity
- Quince Therapeutics, Inc. / CIK 0001662774
- Captured
- 2026-09-21T17:22:27.063Z
- SEC response SHA-256
bc7d1f8395b07fec6552b2264e56a3e39c9a5c7687c209e3471a96c89ecf70a3
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001662774.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))